SCHEMBL1085587

SCHEMBL1085587

CCOC(=O)c1c(C)cc(-c2cncc(C(F)(F)F)c2)nc1C

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
KDM4E B2RXH2 7/20 0.43
HPGD P15428 5/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
MAPT P10636 4/20 0.43
KMT2A Q03164 3/20 0.43
MEN1 O00255 2/20 0.43
TSHR P16473 1/20 0.41
CASP1 P29466 1/20 0.41
CASP7 P55210 1/20 0.41
HSD17B10 Q99714 1/20 0.41
RORC P51449 1/20 0.41
ADORA3 P0DMS8 3/20 0.40
GAA P10253 2/20 0.40
NPC1 O15118 1/20 0.40
LMNA P02545 1/20 0.40
RAB9A P51151 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
CYP1A2 P05177 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1085386 0.85 ALDH1A1 (0.57) ALDH1A1L3MBTL1KDM4EHPGDSMN1; SMN2
SCHEMBL1085393 0.84 ALDH1A1 (0.41) ALDH1A1L3MBTL1KDM4ESMN1; SMN2TRPV3
SCHEMBL3755311 0.81 ALDH1A1 (0.48) ALDH1A1L3MBTL1KDM4EHPGDSMN1; SMN2
SCHEMBL3539265 0.74 ALDH1A1 (0.51) ALDH1A1L3MBTL1KDM4EHPGDSMN1; SMN2
SCHEMBL6017162 0.74 ALDH1A1 (0.82) ALDH1A1L3MBTL1KDM4EHPGDSMN1; SMN2
SCHEMBL1085616 0.74 ALDH1A1 (0.51) ALDH1A1L3MBTL1KDM4EHPGDSMN1; SMN2
SCHEMBL1085197 0.74 ALDH1A1 (0.52) ALDH1A1L3MBTL1KDM4EHPGDSMN1; SMN2
SCHEMBL28836208 0.73 CYP2C19 (0.62) ALDH1A1L3MBTL1KDM4EHPGDSMN1; SMN2
SCHEMBL29937267 0.73 CYP2C19 (0.62) ALDH1A1L3MBTL1KDM4EHPGDSMN1; SMN2
SCHEMBL1085058 0.72 MAPT (0.58) ALDH1A1L3MBTL1KDM4EHPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153805-B2 Biaryl derivatives HOFFMANN-LA ROCHE INC. (US) 2012-04-10 US disclosed
EP-2205583-A2 N-HETEROCYCLIC BIARYL CARBOXAMIDES AS CCR RECEPTOR ANTAGONISTS F. Hoffmann-Roche AG (CH) 2010-07-14 EP disclosed
WO-2009043747-A2 N-HETEROCYCLIC BIARYL CARBOXAMIDES AS CCR RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2009-04-09 WO disclosed
US-20090048238-A1 NOVEL BIARYL DERIVATIVES HOFFMANN-LA ROCHE, INC. 2009-02-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048238-A1 NOVEL BIARYL DERIVATIVES CCR3, CCRL2, CCR2 ALDH1A1 1202/4885L3MBTL1 2710/4885KDM4E 3999/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.